

PTO/SB/81 (06-04)

Approved for use through 11/30/2005. OMB 0651-0035

U.S. Patent and Trademark Office: US DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

POWER OF ATTORNEY and CORRESPONDENCE ADDRESS INDICATION FORM	Application Number	PC1/EP2004/009819
	Filing Date	2 September 2004
	First Named Inventor	Ronnie Maxwell LAWRENCE
	Title	PROCESS FOR THE PREPARATION OF (1S,4R)-CIS-4 '2-AMINO-6CHLORO-9H- PURIN-9-YL1-2-CYCLOPENTENE-1- METHANOL
	Art Unit	
	Examiner Name	
	Attorney Docket Number	PB60476

I hereby appoint:

☒ Practitioners associated with the Customer Numbers. 23347
Or
☐ Practitioner(s) named below:

Name	Registration Number
As my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith.	
Please recognize or change the correspondence address for the above-identified application to:	
<input type="checkbox"/> The address associated with the above-mentioned Customer Number: Or <input checked="" type="checkbox"/> The address associated with Customer Number 23347 Or <input type="checkbox"/> Firm or Individual Name:	
Address:	
Address:	
City:	State: Zip:
Country:	
Telephone:	Fax:
I am the:	
<input type="checkbox"/> Applicant/Inventor: <input checked="" type="checkbox"/> Assignee of record of the entire interest. See 37 CFR 3.71. Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96)	
SIGNATURE of Applicant or Assignee of Record	
Signature:	Date:
Name: Peter John GIDDINGS	Telephone: +44 20 8047 4414
Title and Company: Attorney and Authorised Official, Glaxo Group Limited	
NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below*.	
<input type="checkbox"/> *Total of: forms are submitted.	

This collection of information is required by 37 CFR 1.31 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is essential to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commission for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

BEST AVAILABLE COPY

PB60476/US

Docket No.: PB60476

DECLARATION

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

"PROCESS FOR THE PREPARATION OF (1S,4R)-CIS-4 '2-AMINO-6CHLORO-9H-PURIN-9-YL-1-2-CYCLOPENTENE-1-METHANOL "

the specification of which (check one)

☐ is attached hereto.

☒ was filed on PCT/EP2004/009819
and was amended on

as Serial No. 2 September 2004
(if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) or Section 365(b) of any foreign application(s) for patent or inventor's certificate, or Section 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below any foreign application for patent or inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)

Number	Country	Filing Date	Priority Claimed
0320738.8	GB	4 September 2003	YES

I hereby claim the benefit under Title 35, United States Code, Section 119(e) of any United States provisional application(s) listed below.

Application Number	Filing Date
--------------------	-------------

I hereby claim the benefit under Title 35, United States Code, Section 120 of any United States application(s) or Section 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code, Section 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

BEST AVAILABLE COPY

PB60476/US

<u>Serial No.</u>	<u>Filing Date</u>	<u>Status</u>
-------------------	--------------------	---------------

Direct all correspondence to the address associated with Customer Number 23347.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full Name of Inventor: Ronnie Maxwell LAWRENCE

Inventor's Signature: 

Date: 20th February 2006

Residence: Stevenage, Hertfordshire, GB

Citizenship: Australian

Post Office Address: GlaxoSmithKline
Corporate Intellectual Property
Five Moore Drive, P O Box 13398
Research Triangle Park
North Carolina 27709

BEST AVAILABLE COPY